FR2756737B1 - Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens - Google Patents

Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens

Info

Publication number
FR2756737B1
FR2756737B1 FR9614936A FR9614936A FR2756737B1 FR 2756737 B1 FR2756737 B1 FR 2756737B1 FR 9614936 A FR9614936 A FR 9614936A FR 9614936 A FR9614936 A FR 9614936A FR 2756737 B1 FR2756737 B1 FR 2756737B1
Authority
FR
France
Prior art keywords
thalidomide
parkinson
disease
treatment
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9614936A
Other languages
English (en)
Other versions
FR2756737A1 (fr
Inventor
Alain Boireau
Francoise Bordier
Pierre Dubedat
Marie Christine Dubroeucq
Assunta Imperato
Colette Peny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FR9614936A priority Critical patent/FR2756737B1/fr
Priority to JP52527398A priority patent/JP2001505215A/ja
Priority to PCT/FR1997/002175 priority patent/WO1998024433A1/fr
Priority to EP97948977A priority patent/EP0939636A1/fr
Priority to AU76227/98A priority patent/AU7622798A/en
Publication of FR2756737A1 publication Critical patent/FR2756737A1/fr
Application granted granted Critical
Publication of FR2756737B1 publication Critical patent/FR2756737B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR9614936A 1996-12-05 1996-12-05 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens Expired - Fee Related FR2756737B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR9614936A FR2756737B1 (fr) 1996-12-05 1996-12-05 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
JP52527398A JP2001505215A (ja) 1996-12-05 1997-12-02 パーキンソン病及びパーキンソン症候群の処置のためのサリドマイドの適用
PCT/FR1997/002175 WO1998024433A1 (fr) 1996-12-05 1997-12-02 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
EP97948977A EP0939636A1 (fr) 1996-12-05 1997-12-02 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
AU76227/98A AU7622798A (en) 1996-12-05 1997-12-02 Application of thalidomide to the treatment of Parkinson's disease and Parkisonian syndromes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614936A FR2756737B1 (fr) 1996-12-05 1996-12-05 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens

Publications (2)

Publication Number Publication Date
FR2756737A1 FR2756737A1 (fr) 1998-06-12
FR2756737B1 true FR2756737B1 (fr) 1999-01-08

Family

ID=9498364

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9614936A Expired - Fee Related FR2756737B1 (fr) 1996-12-05 1996-12-05 Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens

Country Status (5)

Country Link
EP (1) EP0939636A1 (fr)
JP (1) JP2001505215A (fr)
AU (1) AU7622798A (fr)
FR (1) FR2756737B1 (fr)
WO (1) WO1998024433A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833850B1 (fr) 2001-12-26 2004-01-23 Look Fixations Sa Dispositif de montage d'un element de fixation utilisee sur une planche de glisse
FR2834904B1 (fr) 2002-01-21 2004-02-20 Look Fixations Sa Planche de glisse et piece amovible formant cache destine a etre monte sur une telle planche
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
JP5339588B2 (ja) * 2008-11-10 2013-11-13 国立大学法人 新潟大学 サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7376394A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders

Also Published As

Publication number Publication date
FR2756737A1 (fr) 1998-06-12
WO1998024433A1 (fr) 1998-06-11
AU7622798A (en) 1998-06-29
EP0939636A1 (fr) 1999-09-08
JP2001505215A (ja) 2001-04-17

Similar Documents

Publication Publication Date Title
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
EE9800158A (et) Epinastiin kasutamiseks valude ravis
NO993979D0 (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
BR9702662A (pt) Utilização do mel composição cosmética ou dermatiológica utilização cosmética da composição processo cosmético
BR9600969A (pt) Método de tratamento de doença inflamatória cardíaca
NO972972L (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
ATE96840T1 (de) Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.
ATA47787A (de) Festes mundpflegemittel gegen zahnstein und mundgeruch
BR9707623A (pt) Composição cosmética processo de tratamento cosmético das matérias queratínicas e utilização da composição
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
IT1212041B (it) Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
AU3886200A (en) Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
FR2756737B1 (fr) Application de la thalidomide au traitement de la maladie de parkinson et des syndromes parkinsoniens
NO995231D0 (no) Terapeutisk behandling av hudlidelser
FR2710839B1 (fr) Composition cosmétique et méthode de traitement esthétique s'opposant au vieillissement de la peau.
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
FR2619713B1 (fr) Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
NO982562D0 (no) Sammensetning for behandling av smerte
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
FR2741804B1 (fr) Application de 2-iminobenzothiazolines dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
FR2774596B1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
FR2765218B1 (fr) Le (s) 3,4,5-trimethoxybenzoate de 2-methylamino-2-phenyl-n- butyle, son application au traitement des douleurs chroniques
FR2700115B1 (fr) Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Legal Events

Date Code Title Description
ST Notification of lapse